| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | growth differentiation factor 8 |
| Clinical data | |
| Other names | REGN1033 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6374H9884N1696O2018S46 |
| Molar mass | 144037.80 g·mol−1 |
Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. Sometimes it is combined with Garetosmab.
Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation.[2]
This drug was developed by Regeneron Pharmaceuticals, Inc.[3]
References
[edit]- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Mastaitis JW, Gomez D, Raya JG, Li D, Min S, Stec M, et al. (May 2025). "GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates". Nature Communications. 16 (1) 4377. Bibcode:2025NatCo..16.4377M. doi:10.1038/s41467-025-59485-9. PMC 12075787. PMID 40360507.
- ^ "Trevogrumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |